...Good morning. This is Jonathan Javitt, Founder, Chief Scientist and Chairman of and NRX Pharmaceuticals. Welcome to our Special Meeting of Shareholders. Before I turn this over to Steve Willard our CEO to conduct our business this morning, I just wanted to offer my personal thanks truly from the bottom of our heart as a company and my personal heart as the founder to the dedicated investors in NRX, who've seen us through a global pandemic in COVID, who've seen us reestablish our business in CNS disease and continued to support us despite massive attacks by the same short sellers that have plagued all or nearly all early startup biotechnology companies. And despite those concerted negative attacks, I'm delighted to share with you that 61% of the shares in our company have already been voted in advance of this meeting. That is 56,781,354 shares as of the close of early living last night. We're delighted that investors have been sufficiently interested in what we're doing -- in to what we're...
